Zesger

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zesger

What is Zesger?

Zesger is a therapeutic medication containing the active substance zibotentan. It belongs to a class of drugs known as endothelin receptor antagonists. This medication is designed to target specific biological pathways involved in the regulation of blood vessel constriction and cellular growth.

Mechanism of Action

The primary function of Zesger is to block the action of endothelin-1, a potent peptide produced by the body that causes blood vessels to narrow. By binding to endothelin A (ETA) receptors, the medication helps to prevent the physiological effects typically associated with excessive endothelin activity. This mechanism is studied for its potential to manage conditions characterized by vascular dysfunction or abnormal tissue remodeling.

Clinical Applications

Zesger has been primarily investigated for its role in treating chronic kidney disease and certain oncological conditions. In the context of renal health, it is evaluated for its ability to reduce protein loss in the urine and slow the progression of kidney damage. In oncology, research has focused on how blocking endothelin receptors might influence the growth and spread of specific types of cancer cells.

General Characteristics

As a systemic treatment, Zesger is typically administered orally. Its development focuses on providing a targeted approach to complex chronic diseases by modulating the internal signaling environment of the affected organs. It is used as part of a supervised medical strategy to address underlying pathological processes rather than just managing immediate symptoms.

What side effects are possible with Zesger?

Possible Side Effects and Safety Information for Zesger

The safety profile for Zesger (lisinopril) is officially categorized based on frequency and affected body systems, as documented in regulatory sources like the FDA and EMA.


Adverse Reaction Scope and Frequency

Adverse effects are grouped by the body system affected. Common reactions are typically reported in 1% to 10% of treated patients, while serious reactions are rare.

Classification System-Organ Class Examples of Documented Reactions
Common Nervous/Respiratory Headache, Dizziness, and a persistent, dry Cough
Uncommon Cardiovascular/Gastrointestinal Orthostatic Hypotension (low blood pressure upon standing), Tachycardia, Nausea, Vomiting, Fatigue
Rare Skin/Hepatobiliary Angioedema (swelling), Hepatic Failure, Pancreatitis

Serious Safety Considerations

The label identifies several reactions as serious or clinically significant:

  • Angioedema: Swelling of the face, tongue, glottis, or larynx, which may occur at any time during treatment.
  • Fetal Toxicity: The drug carries an official warning for causing injury and death to the developing fetus, particularly during the second and third trimesters of pregnancy.
  • Acute Renal Failure: Risk, particularly in patients with pre-existing renal conditions or volume depletion.
  • Hyperkalemia: Elevated serum potassium levels.

Safety Restrictions and Patterns

  • Contraindications: The medicine is formally contraindicated in individuals with a history of Angioedema related to prior ACE inhibitor therapy, and in patients with diabetes or renal impairment taking aliskiren. Concomitant use with a neprilysin inhibitor (e.g., sacubitril/valsartan) is also forbidden.
  • Time-Related Pattern: Hypotension is most likely to occur following the initial dose or during dose escalation.
  • Population Note: Patients with Renal Impairment require lower initial doses and are subject to mandatory monitoring of renal function and serum potassium, as specified by regulatory documents.

Overdose and Emergency Response

Zesger Overdose and when to seek help

The official regulatory profile for Zesger (Lisinopril) overdose is characterized by an exaggerated manifestation of the drug’s intended effect, primarily resulting in severe hemodynamic instability.

Documented Clinical Signs and Severe Outcomes

The most frequent clinical sign of overdose is profound hypotension (extremely low blood pressure), which can manifest as lightheadedness or fainting (syncope). Documented severe outcomes include the progression to cardiovascular shock and the onset of acute renal failure. Overdose also carries the risk of significant electrolyte imbalances, specifically elevated potassium (hyperkalemia) and low sodium (hyponatremia).

Mandated Emergency Action and Management Procedures

Immediate medical attention must be sought if any signs of severe hypotension or syncope occur. Regulatory guidance requires contacting a poison control center or emergency room at once. If the affected individual is collapsed, seizing, experiencing difficulty breathing, or cannot be awakened, emergency services (911) must be called without delay.

Management is limited to symptomatic and supportive treatment because no specific antidote is known. Intervention often involves the administration of an Intravenous (IV) fluid bolus to counteract hypotension. Asymptomatic individuals require professional observation for a minimum of four hours. Symptomatic patients must receive hospital admission and continuous monitoring for at least 24 hours. The drug is officially documented as being removable from circulation by Hemodialysis.

Therapeutic Uses of Zesger

Zesger is considered relevant for the management of cardiovascular and renal conditions. The medication is commonly applied in addressing conditions like high blood pressure (hypertension), heart failure, and in the context of post-acute myocardial infarction (heart attack).


The overall therapeutic role of Zesger is to provide support that helps ease the overall symptom burden associated with systemic cardiovascular strain. In the context of heart failure, it helps address symptom clusters that interfere with daily comfort, such as shortness of breath and fluid retention. For those with diabetes, it plays a role in managing early kidney damage by addressing protein leakage in the urine. This systemic support contributes to improved comfort during periods of physiological stress.

“The therapy aims to provide consistent support for the circulatory system, which may assist with maintaining functional stability of blood pressure and heart function.”

Quick Fact: Support for Cardiovascular Strain Zesger is commonly used to help ease the workload on the heart and circulatory system, which may support the reduction of risk of severe long-term complications.

Regulatory References

  1. DailyMed (NIH) information on Lisinopril

Eligibility and Restrictions for Use

Who can and cannot use Zesger?

This section describes official population-eligibility and non-eligibility rules for Zesger (Lisinopril), as defined by government regulatory agencies.

Contraindicated Populations (Must Not Use)

Classification Rule
Pregnancy Contraindicated, particularly during the second and third trimesters. Discontinue immediately upon detection of pregnancy.
Angioedema History Patients with a history of Angioedema related to any prior ACE Inhibitor or those with hereditary/idiopathic angioedema.
Concomitant Drug Use Patients taking Sacubitril/Valsartan (or within 36 hours of the last dose) or diabetic patients taking Aliskiren.

Age-Related and Conditional Eligibility

Adults are generally eligible for use in all labeled indications. Children are eligible only for the treatment of hypertension if they are 6 years of age and older and meet specific kidney function criteria. Use is not recommended in children under 6 years of age.

Renal Impairment requires conditional use. The medicine is not recommended for pediatric patients with a Glomerular Filtration Rate (GFR) less than 30 mL/min/1.73m^2. Adult patients with reduced kidney function must initiate therapy with a lower starting dose.

Breastfeeding is not recommended due to unknown excretion into human milk and unestablished effects on the infant. Caution is also required for patients with specific heart valve obstructions.

What should I know about interactions with other medicines?

The interaction profile for Zesger (Lisinopril) is defined by official regulatory documentation, focusing on constraints related to the Renin-Angiotensin-Aldosterone System (RAAS) and electrolyte balance.

Contraindicated Combinations and Restrictions

Co-administration with Sacubitril/Valsartan is formally contraindicated due to a significantly increased risk of angioedema. A mandatory separation period of 36 hours is required when switching between these agents. Zesger is also contraindicated with Aliskiren in patients diagnosed with diabetes mellitus or moderate-to-severe renal impairment (GFR below 60 mL/min/1.73 m^2), owing to the documented risks of dual RAAS blockade. Additionally, use with certain high-flux dialysis membranes is prohibited due to the potential for severe, sudden reactions.

Pharmacodynamic and Exposure Interactions

Interactions that increase the risk of hyperkalaemia (elevated serum potassium) include the concomitant use of potassium-sparing diuretics (e.g., Spironolactone), potassium supplements, or other agents that elevate serum potassium. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may result in the attenuation of Zesger’s antihypertensive effect and increase the risk of renal function deterioration. Co-administration with Lithium may lead to reversible increases in serum lithium concentrations and toxicity due to reduced renal clearance of Lithium. Agents such as mTOR inhibitors also pose an increased risk for angioedema. Alcohol may contribute an additive effect, increasing the risk of low blood pressure. Food does not influence Zesger's absorption.

Mechanism of Action

Zesger is a prodrug that is rapidly converted to its active metabolite, which then exerts its effect primarily in hepatic tissue. This active form functions as a competitive inhibitor of HMG-CoA reductase, the enzyme responsible for the rate-limiting step within the mevalonate pathway. This molecular interaction effectively modulates the pathway by curtailing the intracellular de novo biosynthesis of cholesterol.

The subsequent drop in intracellular cholesterol levels initiates a compensatory cellular cascade: the upregulation of surface-bound LDL receptors on hepatocytes. These receptors increase the efficiency of low-density lipoprotein (LDL) particle capture from the bloodstream. The combined effect of reduced hepatic cholesterol synthesis and enhanced plasma LDL clearance results in a measurable, system-level physiological consequence: a significant reduction in circulating plasma LDL-C concentrations.

Dosage and Administration Information

How to Use Zesger — Administration Guidelines

Zesger and its combination products are prescribed based on specific parameters for administration, route, and dosing.

Administration and Dosing

Attribute Instruction Summary
Route and Form Administered orally as a tablet or oral solution.
Timing Should be taken once daily (qDay), consistently at the same time each day.
Meal Relation May be taken with or without food.
Initial Adult Dose Typically 10 mg once daily for uncomplicated hypertension. Lower starting doses (2.5 mg to 5 mg) are utilized for heart failure and specific patient populations.
Dose Titration Adjustments to the dose are generally made at intervals of one to two weeks, based on clinical response, to reach a maintenance dose (e.g., up to 40 mg daily for hypertension).

Special Administration Rules

Renal Impairment: For adult patients with reduced kidney function (creatinine clearance le 30 mL/min), the initial dose is reduced (often halved) to minimize risk. For patients on hemodialysis, the initial dose is 2.5 mg once daily.

Pediatric Dosing: For children aged six years and older being treated for hypertension, the initial dose is calculated by weight: 0.07 mg/kg once daily, with a maximum initial dose of 5 mg.

Concomitant Diuretics: Where clinically possible, diuretics may be discontinued 2 to 3 days prior to starting Zesger to reduce the likelihood of hypotension. If diuretics cannot be stopped, the initial Zesger dose is lower (5 mg or 2.5 mg). The medication is continued long-term for chronic conditions unless otherwise instructed.

Recent Clinical Evidence

Research evidence / Overview of studies for Zesger

Evidence for use in High Blood Pressure (Hypertension)

Research examining Zesger's use in the context of high blood pressure involves numerous Randomized Controlled Trials (RCTs) and long-term studies. These trials were designed to observe changes in measured blood pressure values over defined time intervals, and some research included certain pediatric patients (ages 6 to 16) with hypertension. Findings from these large research efforts consistently reported measurements showing a decrease in blood pressure values in the observed populations. However, evidence is limited regarding the degree of patient response variability among all possible subgroups, and the consistent effect may not be uniform across the full 24-hour dosing interval.

Evidence for use in Symptomatic Heart Failure

The evidence base is built upon large-scale, long-term Randomized Controlled Trials (RCTs) exploring its use as an adjunctive therapy for adult patients with chronic, stable heart failure. Studies monitored outcomes related to the frequency of All-Cause and Cardiovascular Mortality and the rate of hospitalizations. Trials reported patterns related to the frequency of combined mortality and hospitalization in patient groups observed over follow-up periods that spanned several years. The specific contribution of Zesger is complex to separate from the effects of the multiple background medications patients typically receive.

Evidence for Kidney Protection in Proteinuric Disease

Research has explored the use of Zesger in patients with early kidney damage, particularly where the condition is marked by protein leakage (proteinuria) in the urine. Studies monitored the Urinary Albumin-to-Creatinine Ratio and tracked long-term changes in Glomerular Filtration Rate (GFR). Trials consistently reported patterns observed in the studies, showing a reduction in the amount of protein leakage. Studies required follow-up durations long enough to assess both initial, temporary changes in GFR and sustained outcomes.

Key Studies & References Lisinopril in hypertension and diabetes kidney protection clinical evidence (Supported by various guidelines and reviews)

Frequently Asked Questions (FAQ)

Common questions about Zesger (FAQ)

Q: Is Zesger considered a long-term treatment or short-term only?

Official guidance indicates that for chronic conditions, such as high blood pressure or heart failure, Zesger is typically used as a long-term therapy. Studies and regulatory documents note that the blood pressure-lowering effects are generally sustained during continuous long-term treatment.

Q: Is Zesger used for conditions other than the main approved purpose?

Yes, Zesger (lisinopril) is approved for several therapeutic uses as defined in official documents. Its indications include the treatment of high blood pressure (hypertension), the management of heart failure, and reducing the risk of death in patients who are stable after an acute heart attack.

Q: How often are allergic reactions to Zesger reported in studies?

Severe allergic-type reactions, such as angioedema (swelling of the face or throat), are generally classified as rare adverse effects. Regulatory documents note that angioedema is a serious reaction that can occur at any point during the use of Zesger.

Q: Can Zesger be taken with common over-the-counter pain relievers like ibuprofen or acetaminophen?

Official product information advises that combining Zesger with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), like ibuprofen, may reduce the intended blood pressure-lowering effect and potentially increase the risk of worsening kidney function. The regulatory documents primarily focus on interactions with NSAIDs but do not typically list acetaminophen as a major interaction concern.

Q: Has the manufacturer of Zesger conducted any official long-term follow-up studies on patients?

Yes, the regulatory approval of Zesger is supported by extensive clinical studies. This evidence base includes large-scale Randomized Controlled Trials (RCTs) with follow-up periods spanning several years, particularly for its use in chronic conditions like heart failure.

Q: Is Zesger a generic or a brand-name medication?

Zesger is the brand name for the generic medicine Lisinopril. Regulatory bodies confirm that the generic product Lisinopril is widely available and contains the same active ingredient.

Q: Does Zesger contain any commonly discussed substances like aspirin or narcotics?

The active ingredient in Zesger is solely lisinopril. Official drug descriptions confirm that Zesger is a single-ingredient medicine and does not contain aspirin, narcotics, or any other controlled substances.

Q: Do side effects from Zesger typically lessen or go away after a few weeks?

While specific timelines for most side effects are not provided in official labeling, some adverse effects may be transient. The most well-known side effect, a persistent dry cough, is an exception and often continues for as long as the medicine is being taken.

Q: Can Zesger cause unexpected weight gain or loss?

Weight changes are not generally listed among the common or uncommon side effects in regulatory documents. However, certain severe reactions, such as fluid retention or angioedema, can result in swelling or apparent weight gain.

Q: Is hair loss mentioned as a possible side effect in the regulatory documents for Zesger?

Yes, hair loss, also known as alopecia, has been reported in post-marketing safety data for Zesger (lisinopril). This is considered a rare occurrence based on official reports.

Q: Does Zesger have any official warnings related to mood changes or mental clarity?

Official product labeling lists general neurological side effects such as dizziness and headache as common occurrences. The label does not contain explicit warnings about depression or anxiety, though it does list dizziness and headache as common side effects.

Q: What is the official information regarding the risk of dependence or withdrawal with Zesger?

Regulatory information indicates that there is no official statement regarding physical dependence. Unlike some other classes of medication, abrupt withdrawal of Zesger has not been associated with a rapid or uncontrolled increase in blood pressure above pre-treatment levels.

Q: What generally happens if Zesger is stopped suddenly?

Studies have shown that stopping Zesger suddenly is not typically associated with a rapid or significant rebound increase in blood pressure. However, regulatory documents are clear that treatment should be continued long-term for chronic conditions unless otherwise instructed.

Q: Is it possible for the body to develop a tolerance to Zesger over time?

Regulatory documents suggest that the blood pressure-lowering effects of Zesger are generally maintained during continuous long-term therapy. The label notes that the blood pressure-lowering effects are typically maintained during long-term therapy.

Q: What general approaches are described for managing common stomach upset from Zesger?

The drug's administration guidelines state that it may be taken with or without food. Since the drug’s administration guidelines state that it may be taken with or without food, some patients choose to take the medication with a meal if they experience mild stomach upset.

Q: Does Zesger interact with sun exposure or cause photosensitivity?

The official labeling for Zesger (lisinopril) as a single agent does not typically list increased sun sensitivity as a primary side effect. However, product labeling for the combination version that includes hydrochlorothiazide does carry a warning that it can cause photosensitivity.

Q: What is the official statement regarding Zesger and the effectiveness of hormonal birth control?

Official guidance states that Zesger is formally contraindicated in pregnancy due to the risk of fetal toxicity. While adequate contraception is recommended, there is no specific evidence or warning in the product labeling that indicates Zesger reduces the effectiveness of hormonal birth control methods.

Q: Is it possible for Zesger to interact with medications commonly prescribed for high blood pressure?

Yes, regulatory documents identify specific interactions between Zesger and certain other blood pressure medications. Combining it with potassium-sparing diuretics or the renin inhibitor aliskiren is known to increase the risk of kidney complications or elevated serum potassium.

Q: Does Zesger cause drowsiness or impairment that would affect a person's ability to drive?

The product label lists side effects like dizziness, lightheadedness, and fatigue as common or uncommon reactions, especially when treatment begins. These types of effects could potentially cause temporary impairment and affect the ability to operate machinery.

Q: How long does Zesger typically take to start showing an effect?

The onset of the medicine’s blood pressure-lowering activity is generally observed about one hour after taking a dose. This initial effect is the beginning of the desired therapeutic action.

Q: What is the general timeframe to expect the full intended effects of Zesger?

While the peak blood pressure reduction often occurs around six hours after taking the dose, the achievement of the overall optimal blood pressure control may take longer. Regulatory documents state that this full effect may require consistent use for two to four weeks.

Q: What is the standard guidance for a generally healthy patient who missed a dose of Zesger?

General patient information for Zesger advises that if a dose is forgotten, it is typically taken as soon as it is recalled. However, if the time is close to the next scheduled dose, the advice is to continue with the regular schedule. Regulatory guidance typically advises against taking two doses at once to make up for a missed dose.

Q: Can Zesger be crushed or split if a patient has difficulty swallowing tablets?

The official product information does not include explicit instructions allowing the tablet to be crushed or split. Modification of the standard oral tablet form is typically only carried out when a healthcare professional specifically directs it.

How should Zesger be stored and disposed of?

How to Store and Dispose of Zesger (Lisinopril)

The storage and disposal of Zesger must adhere strictly to the conditions specified in official regulatory labeling to maintain the product's stability and integrity.

Official Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F).
Protection Keep the product in its original container, tightly closed, to protect it from moisture and excess heat. Do not freeze the medication.
Child Safety Mandatory to store Zesger out of the sight and reach of children.
Stability The mixed oral solution is stable for up to four weeks when stored at or below room temperature. Do not use Zesger past the expiry date.

Disposal Instructions

Discard any unused or expired Zesger strictly in accordance with local requirements. Official guidance prohibits flushing the medication down the toilet or pouring it into a drain; consult a healthcare professional for the proper discarding method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zesger found in:

A-Z Index: